Your browser doesn't support javascript.
Durability of humoral immune responses to rubella following MMR vaccination.
Crooke, Stephen N; Riggenbach, Marguerite M; Ovsyannikova, Inna G; Warner, Nathaniel D; Chen, Min-Hsin; Hao, Lijuan; Icenogle, Joseph P; Poland, Gregory A; Kennedy, Richard B.
  • Crooke SN; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
  • Riggenbach MM; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
  • Ovsyannikova IG; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
  • Warner ND; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Chen MH; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Hao L; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Icenogle JP; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Poland GA; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
  • Kennedy RB; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA. Electronic address: kennedy.rick@mayo.edu.
Vaccine ; 38(51): 8185-8193, 2020 12 03.
Article in English | MEDLINE | ID: covidwho-997580
ABSTRACT

BACKGROUND:

While administration of the measles-mumps-rubella (MMR-II®) vaccine has been effective at preventing rubella infection in the United States, the durability of humoral immunity to the rubella component of MMR vaccine has not been widely studied among older adolescents and adults.

METHODS:

In this longitudinal study, we sought to assess the durability of rubella virus (RV)-specific humoral immunity in a healthy population (n = 98) of adolescents and young adults at two timepoints ~7 and ~17 years after two doses of MMR-II® vaccination. Levels of circulating antibodies specific to RV were measured by ELISA and an immune-colorimetric neutralization assay. RV-specific memory B cell responses were also measured by ELISpot.

RESULTS:

Rubella-specific IgG antibody titers, neutralizing antibody titers, and memory B cell responses declined with increasing time since vaccination; however, these decreases were relatively moderate. Memory B cell responses exhibited a greater decline in men compared to women.

CONCLUSIONS:

Collectively, rubella-specific humoral immunity declines following vaccination, although subjects' antibody titers remain well above the currently recognized threshold for protective immunity. Clinical correlates of protection based on neutralizing antibody titer and memory B cell ELISpot response should be defined.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rubella / Measles-Mumps-Rubella Vaccine / Immunity, Humoral Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Female / Humans / Male / Young adult Language: English Journal: Vaccine Year: 2020 Document Type: Article Affiliation country: J.vaccine.2020.10.076

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Rubella / Measles-Mumps-Rubella Vaccine / Immunity, Humoral Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Female / Humans / Male / Young adult Language: English Journal: Vaccine Year: 2020 Document Type: Article Affiliation country: J.vaccine.2020.10.076